transmembrane protein 151AGenealiases: DYT36 · EKD3 · TMEM151
Q-omics provides the consensus-scored TMEM151A profile across patient tissues and cancer cell-line models. TMEM151A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM151A is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, TMEM151A RNA expression shows 14,149 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LIHC, and TGCT as cancer lineages where TMEM151A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM151A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM151A survival associations across molecular data types. TMEM151A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM151A RNA expression–survival associations across cancer types. High TMEM151A expression shows unfavorable associations in ACC, DLBC, LUAD, UCEC, BLCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM151A RNA expression.
This table summarizes TMEM151A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM151A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM151A shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA, COAD, CHOL and PAAD. The LIHC box plot shows higher TMEM151A RNA expression in tumor versus normal tissue (log2 FC = +0.807, t-test p < 0.001).
This table shows molecular features associated with TMEM151A in patient tissues and cancer cell lines. In patient samples, TMEM151A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM151A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
